Future studies are needed to investigate more cases to clarify the significance of SLC22A3 methylation level and expression in therapy of AML and to clarify whether SLC22A3 aberrant methylation facilitate or merely coexist with CEBPA mutation. Here, SLC22A3 is linked to acute myeloid leukemia.